SEC Filings

Filing DateFormDescription 
March 26, 20256-KOn March 26, 2025, Biophytis S.A. issued a press release announcing the successful completion of a €2.6 million private placement.PDF
January 21, 20256-KOn January 21, 2025, Biophytis S.A. issued a press release announcing the signing of a co-development agreement with AskHelpU, the largest association in China for those affected by amyotrophic lateral sclerosis (ALS).PDF
January 14, 20256-KOn January 14, 2025, Biophytis S.A. issued a press release announcing that the company enters exclusive negotiations with a Chinese pharmaceutical company to license BIO101.PDF
January 6, 20256-KOn January 6, 2025, Biophytis S.A. (the “Company”) issued a press release announcing the temporary suspension of the listing of its ordinary shares and share warrants on the Euronext Growth market.PDF
September 30, 20246-KOn September 30, 2024, Biophytis S.A. (the “Company”) issued its Interim Financial Report for the first half of fiscal year 2024.PDF
July 22, 20246-KOn July 22, 2024, Biophytis S.A. issued a press release announcing the deployment of its partnership strategy in Asia.PDF
July 11, 20246-KOn July 11, 2024, Biophytis S.A. issued a press release announcing that Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity.PDF
July 1, 20246-KOn July 1, 2024, Biophytis S.A. issued a press release announcing the presentation of its Phase 2-3 COVA study results in severe forms of COVID-19 at the WCID in Paris.PDF
June 20, 20246-KOn June 20, 2024, Biophytis S.A. issued a press release announcing that Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up €108 Million.PDF
June 20, 20246-KOn June 19, 2024, Biophytis S.A. issued a press release announcing that Biophytis extends its contract with Atlas to secure financing for its business activities. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.PDF
June 14, 20246-KOn June 12, 2024, Biophytis S.A. issued a press release announcing the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens.PDF
June 11, 20246-KOn June 10, 2024, Biophytis S.A. issued a press release announcing filing of IND application with the US FDA for its phase 2 study in obesity.PDF
June 7, 20246-KOn June 7, 2024, Biophytis S.A. issued a press release announcing that it will hold a Combined General Meeting (CGM) on June 24, 2024.PDF
May 14, 20246-KOn May 14, 2024, Biophytis S.A. issued a press release announcing the design of its phase 2 OBA clinical study in obesity.PDF
April 29, 20246-KOn April 29, 2024, Biophytis S.A. issued a press release announcing the implementation of a dedicated strategy for partner search in obesity.PDF
April 25, 20246-KOn April 24, 2024, Biophytis S.A. issued a press release announcing the transfer of ADSs to OTC market.PDF
April 18, 20246-KOn April 18, 2024, Biophytis S.A. issued a press release announcing the formation of a new Scientific Advisory Board for its phase 2 OBA clinical study in obesity.PDF
April 15, 20246-KOn April 15, 2024, Biophytis S.A. issued a press release announcing the filing of a patent application and that the company strengthens its intellectual property
in obesity.		PDF
April 9, 20246-KOn April 8, 2024, Biophytis S.A. issued a press release announcing its 2023 financial results and provides an update on its business activities.PDF
April 9, 20246-KOn April 8, 2024, Biophytis S.A. issued a press release announcing that it launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone).PDF
April 8, 202420-FANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the fiscal year ended December 31, 2023.		PDF
April 5, 20246-KOn April 4, Biophytis S.A. issued a press release announcing the results of the Combined General Meeting on April 2, 2024.PDF
March 22, 20246-KOn March 22, 2024, Biophytis S.A. issued a press release announcing that the company presented its phase 3 protocol in the treatment of sarcopenia at the International Conference on Frailty and Sarcopenia Research (ICFSR) held from March 20 to 22, 2024 in Albuquerque, NM, USA.PDF
March 18, 20246-KOn March 18, 2024, Biophytis S.A. issued a press release announcing that a Combined General Meeting will be held on April 2, 2024.PDF
March 15, 20246-KOn March 15, 2024, Biophytis S.A. issued a press release announcing the implementation of a reserve stock split of its ordinary shares.PDF
March 12, 20246-KOn March 12, 2024, Biophytis S.A. issued a press release announcing its participation in several events in Europe and the United States over the coming months.PDF
March 8, 20246-KOn March 8, 2024, Biophytis S.A. issued a press release announcing that the company presented the results of its recent clinical trials with Ruvembri™ at the
Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held from 3 to 6 March 2024 in Orlando, USA.		PDF
January 5, 20246-KOn January 4, 2024, Biophytis S.A. issued a press release announcing the publication of the results of its COV A phase 2-3 study in, eClinicalMedicine, part of The Lancet.PDF
January 5, 20246-KOn December 29, 2023, Biophytis S.A. issued a press release announcing the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract.PDF
December 11, 20236-KOn December 11, 2023, Biophytis S.A. issued a press release announcing its participation in several conferences in Europe and the US during the first quarter of 2024.PDF
December 05, 20236-KOn December 4, 2023, Biophytis S.A. issued a press release announcing that Biophytis and the University of Liège explore the potential of Sarconeos (Ruvembri) in the treatment of viral respiratory failure.PDF
November 21, 20236-KOn November 17, 2023, Biophytis S.A. issued a press release announcing receipt of Nasdaq Notice.PDF
November 20, 20236-KOn November 20, 2023, Biophytis S.A. issued a press release announcing the success of its capital increase with preferential subscription rights for approximately € 1.96 million.PDF
November 7, 20236-KOn November 6, 2023, Biophytis S.A. issued a press release announcing that the company is attending the BIO-Europe conference held in Munich, Germany, November 6th to 8th 2023.PDF
October 30, 20236-KOn October 30, 2023, Biophytis S.A. issued a press release announcing that Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (Ruvembri) in Brazil.PDF
October 26, 20236-KOn October 27, 2023, Biophytis S.A. issued a press release, a copy of which is attached as Exhibit 99.1 to this Form 6-K.PDF
October 23, 20236-KOn October 23, 2023, Biophytis S.A. issued a press release announcing the launch of a rights issue with maintenance of shareholders’ preferential subscription rights to continue the execution of its strategic roadmap.PDF
September 27, 20236-KOn September 27, 2023, Biophytis S.A. (the “Company”) issued its Interim Financial Report for the first half of fiscal year 2023.PDF
September 25, 20236-KOn September 25, 2023, Biophytis S.A. issued a press release announcing that Biophytis and Skyepharma have signed a Partnership Agreement for the Production of Sarconeos (Ruvembri).PDF
September 19, 20236-KOn September 19, 2023, Biophytis S.A. issued a press release providing an update on its early access programs for Sarconeos (Ruvembri) in the treatment of severe forms of COVID-19.PDF
September 14, 20236-KOn September 14, 2023, Biophytis S.A. issued a press release announcing that Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer.PDF
September 11, 20236-KOn September 11, 2023, Biophytis S.A. issued a press release announcing that it has obtained FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia.PDF
September 4, 20236-KOn September 4, 2023, Biophytis S.A. issued a press release announcing its participation at the H. C. Wainwright 25th Global Investment Conference in New York.PDF
August 16, 20236-KOn August 16, 2023, Biophytis S.A. issued a press release announcing next regulatory steps in Europe and the United States for its COVA project.PDF
August 8, 20236-KOn August 8, 2023, Biophytis S.A. issued a press release announcing that it received a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe.PDF
July 21, 20236-KOn July 18, 2023, Biophytis S.A. entered into an investor subscription agreement with an institutional investor, pursuant to which the Company agreed to sell and issue to the investor 505,000 units of ordinary shares with ordinary warrants attached.PDF
July 20, 20236-KOn July 20, 2023, Biophytis S.A. issued a press release announcing it has requested a pre-submission meeting with the FDA for an Emergency Use Authorization of Sarconeos (Ruvembri) for the treatment for COVID 19.PDF
July 19, 20236-KOn July 19, 2023, Biophytis S.A. issued a press release announcing $3.8 Million Registered Direct OfferingPDF
July 18, 20236-KOn July 18, 2023, Biophytis S.A. issued a press release announcing that Biophytis and Seqens have signed a partnership to produce Sarconeos (Ruvembri) active compound.PDF
July 10, 20236-KOn July 10, 2023, Biophytis S.A. issued a press release announcing it has filed with the FDA for authorization to initiate SARA-31 phase 3 study in sarcopenia.PDF
July 3, 2023F-3F-3
Registration Statement		PDF
July 3, 202320-F/AAmendment No.1 to Form 20-F/A filed on April 19, 2023.PDF
June 19, 20236-KOn June 19, 2023, Biophytis S.A. issued a press release announcing that it reports clinical results for Sarconeos (Ruvembri) in sarcopenia treatment at the 16th SCWD International Congress.PDF
June 16, 20236-KOn June 16, 2023, Biophytis S.A. issued a press release announcing the approval by a large majority of all resolutions presented by the company and falling within the remit of the Annual General Meeting.PDF
June 5, 20236-KOn June 5, 2023, Biophytis S.A. issued a press release announcing its participation at the BIO International Convention in Boston from the 5th to the 8th of June.PDF
May 26, 20236-KOn May 26, 2023, Biophytis S.A. issued a press release announcing that the company has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (Ruvembri).PDF
May 25, 20236-KOn May 25, 2023, Biophytis S.A. issued a press release announcing its presentation of positive results of Phase 2-3 COVA study at the American Thoracic Society International Conference.PDF
May 15, 20236-KOn May 15, 2023, Biophytis S.A. issued a press release announcing that the company has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia.PDF
May 11, 20236-KOn May 11, 2023 Biophytis S.A. issued a press release announcing a successful capital increase with €2.3 million raised.PDF
May 9, 20236-KOn May 9, 2023, Biophytis S.A. issued a press release announcing it has requested a pre-submission meeting with the EMA for the Marketing Authorisation of Sarconeos (Ruvembri) for the treatment of COVID-19PDF
May 2, 20236-KOn May 2, 2023, On May 2, 2023, Biophytis S.A. issued a press release announcing the strengthening of its management team.PDF
April 28, 20236-KOn April 28, 2023, Biophytis S.A. issued a press release announcing receipt of Nasdaq Notice.PDF
April 19, 20236-KOn April 19, 2023, Biophytis S.A. issued a press release announcing that Biophytis regains compliance with NASDAQ minimum bid price requirement.PDF
April 19, 202320-F/AAnnual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2022PDF
April 18, 20236-KOn April 18, 2023, Biophytis S.A. issued a press release announcing 2022 Financial Results and 2023 Perspectives. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.PDF
March 31, 20236-KOn March 31, 2023, Biophytis S.A. issued a press release informing that the Extraordinary General Meeting of the company held on March 30, 2023 could not be held on first notice, as the required quorum was not reached. The quorum necessary for holding an extraordinary General Meeting on first call IS 25%.PDF
March 27, 20236-KOn March 27, 2023, Biophytis S.A. issued a press release announcing the presentation of Sarconeos (Ruvembri) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Research (ICFSR).PDF
March 20, 20236-KOn March 20, 2023, Biophytis S.A. issued a press release announcing the presentation of Sarconeos’ (Ruvembri) Development as a Drug Candidate in Rare Neuromuscular Diseases at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.PDF
March 17, 20236-KOn March 17, 2023, Biophytis S.A. issued a press release announcing ratio change under its American Depository Receipt (“ADR”) program.PDF
March 09, 20236-KOn March 9, 2023, Biophytis S.A. issued a press release presenting positive results of Phase 2-3 COVA Study at ERS 2023 21st Lung Science Conference.PDF
March 02, 20236-KOn March 2nd, 2023, Biophytis S.A. issued a press release announcing the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (Ruvembri) in France for the treatment of severe forms of COVID-19.PDF
February 23, 20236-KOn February 23, 2023, Biophytis S.A. issued a press release announcing it is convening an Extraordinary and Ordinary Shareholder’s Meeting for March 30, 2023.PDF
February 02, 20236-KOn February 2, 2023, Biophytis S.A. issued a press release announcing positive final results of the phase 2-3 COVA study with Sarconeos (B10101) in severe COVID-19.PDF
January 31, 20236-KOn January 31, 2023, Biophytis S.A. issued a press release announcing the publication of its interim financial report for the first half of 2022 and its adjusted financial results as of 31 December 2021.PDF
January 31, 202320-F/AAnnual report pursuant to section 13 or 15(d) of the securities exchange act of 1934PDF
January 30, 20236-KOn January 30, 2023, Biophytis S.A. (the “Company” issued its Interim Financial Report for the first half of fiscal year 2022.PDF
January 19, 20236-KOn January 19, 2023, Biophytis S.A. issued a press release announcing that the Paris Court of appeal confirms the judgement of the Paris Commercial Court of 16th March 2021.PDF
January 06, 20236-KOn January 5, 2023, Biophytis S.A. issued a press release announcing its participation in two major investor conferences in January, in the United States and in France : the JP Morgan Healthcare Conference and the Invest Securities Biomed Event.PDF
November 30, 20226-KOn November 30, 2022, Biophytis S.A. issued a press release announcing the organization of a webcast with key opinion leaders (KOL) on the phase 2-3 COVA study results of Sarconeos (Ruvembri) in the treatment of pneumonia in COVID-19 patients at risk of respiratory failure.PDF
October 31, 20226-KOn October 31, 2022, Biophytis S.A. issued a press release announcing the publication of its key financial figures as at 30 June 2022 and a restatement of the financial statements published as of December 31st, 2021 and providing and update on the operational milestones.PDF
October 26, 20226-KOn October 26, 2022, Biophytis S.A. issued a press release announcing receipt of Nasdaq Notice.PDF
September 15, 20226-KOn September 15, 2022, Biophytis S.A. issued a press release announcing that the company will participate in HCW 24th Annual Global Investment conference.PDF
September 13, 20226-KOn September 13, 2022, Biophytis S.A. issued a press release announcing that the Paris Court of appeal rules in favour of Biophytis in the case against Negma Group Ltd.PDF
September 07, 20226-KOn September 7, 2022, Biophytis S.A. issued a press release announcing very promising top line results of its phase 2-3 COVA clinical study in COVID-19 related to respiratory failure.PDF
July 04, 20226-KOn July 4, 2022, Biophytis S.A. issued a press release providing an update on the development of Sarconeos (Ruvembri) in Covid-19 at the 4th Annual Longevity Therapeutics Summit.PDF
June 30, 20226-KOn June 30, 2022, Biophytis S.A. issued a press release announcing the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million.PDF
June 27, 20226-KOn June 27, 2022, Biophytis S.A. issued a press release presenting the development of Sarconeos (Ruvembri) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress.PDF
June 22, 20226-KOn June 22, 2022, Biophytis S.A. issued a press release announcing the results of the Combined General Meeting held on June 21, 2022.PDF
June 16, 20226-KOn June 16, 2022, Biophytis S.A. issued a press release presenting preclinical efficacy data for Sarconeos (Ruvembri) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease.PDF
June 3, 20226-KOn June 3, 2022, Biophytis S.A. issued a press release announcing the Convening of Another Combined General Meeting at a Later Date.PDF
May 12, 20226-KOn May 12, 2022, Biophytis S.A. issued a press release announcing its participation at the Bio International Convention in San Diego from the 13th to the 16th of JunePDF
April 21, 202220-FAnnual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934
For The Fiscal Year Ended December 31, 2021		PDF
April 19, 20226-KOn April 19, 2022, Biophytis S.A. issued a press release announcing that the company will present Sarconeos (Ruvembri) Development Program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston, April 20-22, 2022PDF
April 7, 20226-KOn April 7, 2022, Biophytis S.A. issued a press release announcing 2021 Operational and Financial Results and Gives Updates on 2022 PerspectivesPDF
April 5, 20226-KOn April 5, 2022, Biophytis S.A. issued a press release announcing the appointment of Philippe Rousseau as Chief Financial OfficerPDF
March 16, 20226-KOn March 16, 2022, Biophytis S.A. issued a press release announcing that the company will participate in a key conference on mobility for the elderlyPDF
February 4, 20226-KOn February 3, 2022, Biophytis S.A. issued a press release announcing that the company received approval from ANVISA (Brazil) to give access to Sarconeos (Ruvembri) to hospitalized COVID-19 patients through an Expanded Access ProgramPDF
December 23, 20216-KOn December 22, 2021, Biophytis S.A. issued a press release announcing the drawing of the last tranche of ORNANE under the 2020 Atlas contract for 3 million.PDF
December 17, 20216-KOn December 16, 2021, Biophytis S.A. issued a press release announcing that the company is to meet with FDA to advance Sarconeos (Ruvembri) development in Sarcopenia from Phase 2 to Phase 3PDF
November 23, 20216-KOn November 22, 2021, Biophytis S.A. issued a press release announcing the obtaining of a new 10M€ loan structure with Kreos CapitalPDF
November 15, 20216-KOn November 15, 2021, Biophytis S.A. issued a press release announcing US centers to restart recruitment for the COVA phase 2-3 study with Sarconeos (Ruvembri) in COVID 19PDF
October 29, 20216-KOn October 29, 2021, Biophytis S.A. issued a press release reporting Restated Financial Statements for Previous Periods and as of June 30, 2021.PDF
October 29, 202120-F

Annual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934

For The Fiscal Year Ended December 31, 2020

PDF
October 29, 20216-KOn October 28, 2021, Biophytis S.A. (the “Company” issued its Interim Financial Report for the first half of fiscal year 2021.PDF
October 06, 20216-KBiophytis S.A. issued a press release announcing it will host a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (Ruvembri) for the treatment of COVID-19 and SarcopeniaPDF
October 05, 20216-KOn October 4, 2021, Biophytis S.A. issued a press release announcing the drawing of 2 new tranches of ORNANE under the 2020 Atlas contract for € 6 millionPDF
October 04, 20216-KBiophytis announces promising full results from the SARA-INT Phase 2b trial of Sarconeos (Ruvembri) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR)
September 29 – October 2, 2021		PDF
September 30, 20216-KBiophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (Ruvembri) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29–October 2, 2021PDF
September 17, 20216-KBiophytis reports H1 2021 financial results and provides business updatePDF
September 15, 20216-KBiophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (Ruvembri) in COVID-19PDF
June 30, 20216-KBiophytis announces that the results of SARA-INT Phase 2 Trial with Sarconeos (Ruvembri) in Sarcopenia will be released by August 2021PDF
June 30, 20216-KBiophytis announces that it will secure the manufacturing of Sarconeos (Ruvembri) for COVID-19 with a global CDMO and the next milestones for the COVA Phase 2-3 studyPDF
June 18, 20216-KBiophytis announces new convertible bonds financing upt to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 millionPDF
May 12, 20216-KBiophytis Completed the Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (Ruvembri) in COVID-19 allowing the 2nd Interim AnalysisPDF
May 11, 20216-KResults of the Combined General Meeting on May 10, 2021PDF
April 30, 20216-KBiophytis Second Combined General Meeting to take place on May 10, 2021 without the physical presence of its shareholersPDF
April 29, 20216-KBiophytis Receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMDPDF
April 27, 20216-KConvening of another Combined General Meeting at a later datePDF
April 26, 20216-KBiophytis gives operational perspectives on its Sarconeos (Ruvembri) ahead of its upcoming AGM on April 26, 2021PDF
March 22, 20216-KBiophytis gives update on its Phase 2-3 COVA study on COVID-19PDF
March 19, 20216-KJudgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group LtdPDF
March 12, 20216-KAnnual General Meeting will take place on April 26, 2021PDF
March 11, 202120-FAnnual Report for the Fiscal Year Ended Dec 31, 2020PDF
Feb 26, 20216-KBiophytis Reports 2020 Full Year ResultsPDF
Feb 17, 20216-KExpansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA TrialPDF
Feb 16, 20216-KReport of Foreign Private IssuerPDF
Feb 9, 2021 Final ProspectusPDF
Feb 9, 2021F-1Amendment No 3PDF
Feb 8, 2021FWPFree Writing ProspectusPDF
Feb 4, 2021F-8AFor Registration of Certain Classes of Securities Pursuant to Section 12(b) or (g)PDF
Feb 4, 2021F-1Amendment No 2PDF
Feb 2, 2021FWPFree Writing ProspectusPDF
Feb 2, 2021F-1Amendment No 1PDF
Jan 19, 2021F-1Form F-1PDF
Dec 23, 2020F-1Draft Registration StatementPDF
Nov 20, 2020F-1Draft Registration StatementPDF